As CTRP9 exhibits protective effects in the heart and their levels are associated with cardiovascular events, we imply that future investigations of potential clinic applications should focus on: (a) whether the changes in CTRP9 levels can identify a population at high‐risk for cardiovascular diseases; (b) how to prevent CTRP9 levels from decreasing with ageing; and (c) how to maintain CTRP9 at appropriate levels to protect against cardiovascular diseases. This evidence concerns the gene C1QTNF9 and cardiovascular disorder.